Kennedy Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Kennedy Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-203,823	Closed	-$4.42M	–	790
2017 Q2	$4.42M	Buy	+203,823	New	+$3.7M	0.08%	439
2016 Q3	–	Sell	-46,248	Closed	-$622K	–	778
2016 Q2	$622K	Buy	46,248 +4,491	+11%	+$65.5K	0.01%	666
2016 Q1	$638K	Hold	41,757	–	–	0.01%	684
2015 Q4	$829K	Buy	41,757 +6,216	+17%	+$118K	0.02%	673
2015 Q3	$619K	Sell	35,541 -4,422	-11%	-$90K	0.01%	680
2015 Q2	$808K	Sell	39,963 -10,910	-21%	-$211K	0.01%	683
2015 Q1	$895K	Buy	+50,873	New	+$867K	0.02%	666

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Kennedy Capital Management's AMRI Position: Q3 2017 in Review

Kennedy Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 203,823 shares — an estimated $4.42M sold.

Kennedy Capital Management first reported a position in AMRI in Q1 2015 and held it in 7 quarters. The position peaked at $4.42M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Kennedy Capital Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Kennedy Capital Management sold 203,823 Albany Molecular Research Inc shares in Q3 2017, an estimated $4.42M.
Kennedy Capital Management first reported a position in Albany Molecular Research Inc in Q1 2015 and held it in 7 quarters.
Kennedy Capital Management's Albany Molecular Research Inc position peaked at $4.42M in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Kennedy Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.